Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in bladder cancer, positioning the Big Pharma to file for approval of an ...

Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.

Pfizer acquired a smaller company for $4.9 billion to improve its prospects in the GLP-1 market. The pharmaceutical giant could carve out a small niche for itself in this growing space. Pfizer's ...

Pfizer stock (NYSE: PFE) currently trades at $29 per share, 45% below its peak level of $54 seen in December 2021. In contrast, Merck stock is up 54% over this period. PFE stock was trading at $47 in ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

Pfizer (PFE) announced early Monday that it is halting a late-stage trial of its GLP-1 pill candidate, danuglipron, dashing hopes of the company entering the obesity space in the near term. A trial ...